Enanta Pharmaceuticals Inc
ENTA7.030USD
-0.080-1.13%
Horário de mercado （ET）Cotações atrasadas em 15 min
150.28MValor de mercado
PerdaP/L TTM
Mais detalhes de Enanta Pharmaceuticals Inc Empresa
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Informações da empresa
Código da empresaENTA
Nome da EmpresaEnanta Pharmaceuticals Inc
Data de listagemMar 21, 2013
CEODr. Jay R. Luly, Ph.D.
Número de funcionários131
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 21
Endereço4 Kingsbury Avenue
CidadeWATERTOWN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02472
Telefone16176070800
Sitehttps://www.enanta.com/
Código da empresaENTA
Data de listagemMar 21, 2013
CEODr. Jay R. Luly, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
826.73K
+8.19%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
362.33K
+1.52%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
22.95K
+22.24%
Dr. Tara L. Kieffer, Ph.D.
Dr. Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
Chief Product Strategy Officer
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Mr. Paul J. Mellett, Jr.
Mr. Paul J. Mellett, Jr.
Chief Financial and Administrative Officer
Chief Financial and Administrative Officer
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Independent Director
Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Independent Director
Independent Director
--
--
Dr. Lesley Russell
Dr. Lesley Russell
Independent Director
Independent Director
--
--
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
826.73K
+8.19%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
362.33K
+1.52%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
22.95K
+22.24%
Dr. Tara L. Kieffer, Ph.D.
Dr. Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
Chief Product Strategy Officer
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Mr. Paul J. Mellett, Jr.
Mr. Paul J. Mellett, Jr.
Chief Financial and Administrative Officer
Chief Financial and Administrative Officer
--
--
Detalhamento da receita
FY2025Q2
FY2024
FY2024Q2
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
14.93M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Farallon Capital Management, L.L.C.
9.93%
Krensavage Asset Management, LLC
9.90%
The Vanguard Group, Inc.
9.39%
BlackRock Institutional Trust Company, N.A.
8.05%
Millennium Management LLC
6.30%
Other
56.43%
Investidores
Investidores
Proporção
Farallon Capital Management, L.L.C.
9.93%
Krensavage Asset Management, LLC
9.90%
The Vanguard Group, Inc.
9.39%
BlackRock Institutional Trust Company, N.A.
8.05%
Millennium Management LLC
6.30%
Other
56.43%
Tipos de investidores
Investidores
Proporção
Investment Advisor
35.82%
Hedge Fund
25.06%
Investment Advisor/Hedge Fund
23.43%
Individual Investor
6.69%
Research Firm
2.01%
Bank and Trust
0.30%
Family Office
0.20%
Sovereign Wealth Fund
0.19%
Pension Fund
0.15%
Other
6.14%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
315
20.05M
93.80%
-6.87M
2025Q1
342
20.11M
94.09%
-7.55M
2024Q4
348
21.38M
100.27%
-5.34M
2024Q3
354
22.65M
106.92%
-6.74M
2024Q2
352
23.60M
111.43%
-6.27M
2024Q1
361
24.29M
114.84%
-4.07M
2023Q4
373
21.96M
104.28%
-4.11M
2023Q3
375
22.04M
104.75%
-4.91M
2023Q2
376
21.98M
104.47%
-3.80M
2023Q1
380
21.64M
103.62%
-3.43M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Farallon Capital Management, L.L.C.
2.12M
9.93%
+14.00K
+0.66%
Mar 31, 2025
Krensavage Asset Management, LLC
2.12M
9.9%
-804.00
-0.04%
Mar 31, 2025
The Vanguard Group, Inc.
2.01M
9.39%
+23.27K
+1.17%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
8.05%
+3.27K
+0.19%
Mar 31, 2025
Millennium Management LLC
1.35M
6.3%
-35.34K
-2.56%
Mar 31, 2025
Acadian Asset Management LLC
867.04K
4.06%
+17.61K
+2.07%
Mar 31, 2025
Marshall Wace LLP
850.89K
3.98%
-79.20K
-8.52%
Mar 31, 2025
Luly (Jay R)
826.73K
3.87%
+62.57K
+8.19%
Feb 12, 2025
Stonepine Capital Management, LLC
590.74K
2.76%
+258.84K
+77.99%
Mar 31, 2025
Geode Capital Management, L.L.C.
494.20K
2.31%
+16.97K
+3.56%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.57%
iShares Micro-Cap ETF
0.03%
Vanguard US Value Factor ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Avantis US Small Cap Equity ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.57%
iShares Micro-Cap ETF
Proporção0.03%
Vanguard US Value Factor ETF
Proporção0.02%
ProShares Ultra Nasdaq Biotechnology
Proporção0.02%
Avantis US Small Cap Equity ETF
Proporção0.02%
Invesco Nasdaq Biotechnology ETF
Proporção0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.02%
Global X Russell 2000 ETF
Proporção0.01%
iShares Russell 2000 Value ETF
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
